{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:41:18Z","timestamp":1761561678686,"version":"build-2065373602"},"reference-count":75,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.rdc.2012.08.008","type":"journal-article","created":{"date-parts":[[2012,9,7]],"date-time":"2012-09-07T06:00:22Z","timestamp":1346997622000},"page":"663-680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Safety of Urate-Lowering Therapies"],"prefix":"10.1016","volume":"38","author":[{"given":"Robert T.","family":"Keenan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2012.08.008_bib1","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.008_bib2","first-page":"2403","article-title":"Epidemiology of gout: is the incidence rising?","volume":"29","author":"Arromdee","year":"2002","journal-title":"J\u00a0Rheumatol"},{"issue":"Suppl 5","key":"10.1016\/j.rdc.2012.08.008_bib3","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.3949\/ccjm.75.Suppl_5.S9","article-title":"Epidemiology of gout","volume":"75","author":"Weaver","year":"2008","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.rdc.2012.08.008_bib4","doi-asserted-by":"crossref","first-page":"a2467","DOI":"10.1136\/bmj.a2467","article-title":"Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study","volume":"337","author":"Driver","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.rdc.2012.08.008_bib5","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.jacc.2010.11.041","article-title":"Community prevalence of ideal cardiovascular health, by the American Heart Association definition, and relationship with cardiovascular disease incidence","volume":"57","author":"Folsom","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.rdc.2012.08.008_bib6","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1001\/archinte.165.7.742","article-title":"Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study","volume":"165","author":"Choi","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.rdc.2012.08.008_bib7","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","article-title":"Independent impact of gout on mortality and risk for coronary heart disease","volume":"116","author":"Choi","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.rdc.2012.08.008_bib8","first-page":"199","article-title":"Gout and its comorbidities","volume":"68","author":"Pillinger","year":"2010","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"10.1016\/j.rdc.2012.08.008_bib9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","article-title":"Prevalence of contraindications and prescription of pharmacologic therapies for gout","volume":"124","author":"Keenan","year":"2011","journal-title":"Am J Med"},{"issue":"7","key":"10.1016\/j.rdc.2012.08.008_bib10","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","article-title":"Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008","volume":"125","author":"Zhu","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.rdc.2012.08.008_bib11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/ard.2004.024091","article-title":"Gout epidemiology: results from the UK General Practice Research Database, 1990-1999","volume":"64","author":"Mikuls","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.008_bib12","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/01.rhu.0000147049.12220.32","article-title":"Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting","volume":"10","author":"Riedel","year":"2004","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.rdc.2012.08.008_bib13","doi-asserted-by":"crossref","first-page":"842","DOI":"10.7326\/0003-4819-62-4-842","article-title":"Allopurinol in the treatment of gout","volume":"62","author":"Wyngaarden","year":"1965","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2012.08.008_bib14","first-page":"372","article-title":"The clinical and metabolic effects of benemid in patients with gout","volume":"64","author":"Talbott","year":"1951","journal-title":"Trans Assoc Am Physicians"},{"key":"10.1016\/j.rdc.2012.08.008_bib15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.rhu.0000209882.50228.9f","article-title":"Serum urate levels and gout flares: analysis from managed care data","volume":"12","author":"Sarawate","year":"2006","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.rdc.2012.08.008_bib16","first-page":"562","article-title":"Medication errors with the use of allopurinol and colchicine: a retrospective study of a national, anonymous Internet-accessible error reporting system","volume":"33","author":"Mikuls","year":"2006","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2012.08.008_bib17","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/keh679","article-title":"Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD)","volume":"44","author":"Mikuls","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2012.08.008_bib18","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","article-title":"Gout medication treatment patterns and adherence to standards of care from a managed care perspective","volume":"81","author":"Sarawate","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.rdc.2012.08.008_bib19","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.008_bib20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/MLR.0b013e31825852f0","article-title":"Communicating the risks of medicine: time to move forward","volume":"50","author":"Dal Pan","year":"2012","journal-title":"Med Care"},{"key":"10.1016\/j.rdc.2012.08.008_bib21","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1345\/aph.1L037","article-title":"Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies","volume":"42","author":"Kongkaew","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.rdc.2012.08.008_bib22","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/rheumatology\/keq346","article-title":"Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout","volume":"50","author":"Khanna","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2012.08.008_bib23","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2165\/11592290-000000000-00000","article-title":"Difficult-to-treat gouty arthritis: a disease warranting better management","volume":"71","author":"Schlesinger","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.rdc.2012.08.008_bib24","article-title":"Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy","author":"Wu","year":"2011","journal-title":"Am J Ther"},{"key":"10.1016\/j.rdc.2012.08.008_bib25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1124\/pr.58.1.6","article-title":"Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.rdc.2012.08.008_bib26","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3899\/jrheum.101160","article-title":"Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout","volume":"38","author":"Stocker","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2012.08.008_bib27","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0140-6736(84)91807-5","article-title":"Fatal Stevens-Johnson syndrome in a patient on captopril and allopurinol","volume":"1","author":"Pennell","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.rdc.2012.08.008_bib28","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(84)92190-1","article-title":"Fever, myalgia, and arthralgia in a patient on captopril and allopurinol","volume":"1","author":"Samanta","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.rdc.2012.08.008_bib29","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1378\/chest.108.2.586","article-title":"Allopurinol and enalapril. Drug induced anaphylactic coronary spasm and acute myocardial infarction","volume":"108","author":"Ahmad","year":"1995","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.rdc.2012.08.008_bib30","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.008_bib31","first-page":"S542","article-title":"The incidence of allopurinol hypersensitivity syndrome: a population perspective","volume":"60","author":"Khanna","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.008_bib32","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/00007611-197911000-00004","article-title":"Severe hypersensitivity reactions to allopurinol","volume":"72","author":"Lang","year":"1979","journal-title":"South Med J"},{"key":"10.1016\/j.rdc.2012.08.008_bib33","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.rdc.2012.08.008_bib34","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1525-139X.2007.00270.x","article-title":"Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events","volume":"20","author":"Dalbeth","year":"2007","journal-title":"Semin Dial"},{"key":"10.1016\/j.rdc.2012.08.008_bib35","first-page":"384","article-title":"Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction?","volume":"49","author":"Lee","year":"2008","journal-title":"Singapore Med J"},{"key":"10.1016\/j.rdc.2012.08.008_bib36","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1046\/j.1365-2125.1999.00041.x","article-title":"Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects","volume":"48","author":"Turnheim","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rdc.2012.08.008_bib37","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.rdc.2012.08.008_bib38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A\u00a0European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.rdc.2012.08.008_bib39","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.rdc.2012.08.008_bib40","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/FPC.0b013e32834282b8","article-title":"Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans","volume":"21","author":"Kang","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.rdc.2012.08.008_bib41","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1023\/B:CARD.0000015855.02485.e3","article-title":"Cardiovascular drugs and serum uric acid","volume":"17","author":"Reyes","year":"2003","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.rdc.2012.08.008_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.rdc.2012.08.008_bib43","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1053\/meta.2001.19489","article-title":"Effect of furosemide on renal excretion of oxypurinol and purine bases","volume":"50","author":"Yamamoto","year":"2001","journal-title":"Metabolism"},{"issue":"9","key":"10.1016\/j.rdc.2012.08.008_bib44","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/rheumatology\/kes091","article-title":"Furosemide increases plasma oxypurinol without lowering serum urate\u2014a complex drug interaction: implications for clinical practice","volume":"51","author":"Stamp","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2012.08.008_bib45","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/clpt.2011.113","article-title":"Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level","volume":"90","author":"Stamp","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.rdc.2012.08.008_bib46","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1056\/NEJM199602153340707","article-title":"The management of gout","volume":"334","author":"Emmerson","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2012.08.008_bib47","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/rheumatology\/26.6.445","article-title":"Plasma oxipurinol concentrations during allopurinol therapy","volume":"26","author":"Emmerson","year":"1987","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.rdc.2012.08.008_bib48","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout","volume":"33","author":"Dalbeth","year":"2006","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2012.08.008_bib49","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/ard.60.10.981","article-title":"Relation between adverse events associated with allopurinol and renal function in patients with gout","volume":"60","author":"Vazquez-Mellado","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.008_bib50","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/art.1780310318","article-title":"Some adverse reactions to allopurinol may be mediated by lymphocyte reactivity to oxypurinol","volume":"31","author":"Emmerson","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.008_bib51","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2012.08.008_bib52","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.008_bib53","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2012.08.008_bib54","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.lfs.2004.10.031","article-title":"Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase\/xanthine dehydrogenase","volume":"76","author":"Takano","year":"2005","journal-title":"Life Sci"},{"key":"10.1016\/j.rdc.2012.08.008_bib55","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1358\/dot.2009.45.4.1354217","article-title":"Febuxostat: a new agent for lowering serum urate","volume":"45","author":"Keenan","year":"2009","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.rdc.2012.08.008_bib56","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/00498250801956350","article-title":"In\u00a0vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition","volume":"38","author":"Mukoyoshi","year":"2008","journal-title":"Xenobiotica"},{"key":"10.1016\/j.rdc.2012.08.008_bib57","unstructured":"Effect of febuxostat on renal function in patients with gout and moderate to severe renal impairment. 2012. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01082640?term=febuxostat&rank=4. Accessed July 30, 2012."},{"key":"10.1016\/j.rdc.2012.08.008_bib58","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3899\/jrheum.110092","article-title":"Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions","volume":"38","author":"Chohan","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2012.08.008_bib59","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/j.clinthera.2009.11.033","article-title":"Febuxostat: a selective xanthine-oxidase\/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout","volume":"31","author":"Ernst","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.rdc.2012.08.008_bib60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ahj.2011.09.021","article-title":"A\u00a0cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder","volume":"163","author":"White","year":"2012","journal-title":"Am Heart J"},{"year":"2012","series-title":"Krystexxa (pegloticase): prescribing information","key":"10.1016\/j.rdc.2012.08.008_bib61"},{"key":"10.1016\/j.rdc.2012.08.008_bib62","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/art.22403","article-title":"Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout","volume":"56","author":"Sundy","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.008_bib63","doi-asserted-by":"crossref","first-page":"14351","DOI":"10.1073\/pnas.1001072107","article-title":"Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in\u00a0vivo","volume":"107","author":"Hershfield","year":"2010","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.rdc.2012.08.008_bib64","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.rdc.2012.08.008_bib65","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.annemergmed.2006.01.018","article-title":"Second symposium on the definition and management of anaphylaxis: summary report\u2014second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium","volume":"47","author":"Sampson","year":"2006","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.rdc.2012.08.008_bib66","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/art.23810","article-title":"Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study","volume":"58","author":"Sundy","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2012.08.008_bib67","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.008_bib68","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/archinte.1955.00250070099012","article-title":"Probenecid (benemid); its uses and side-effects in 2,502 patients","volume":"95","author":"Boger","year":"1955","journal-title":"AMA Arch Intern Med"},{"key":"10.1016\/j.rdc.2012.08.008_bib69","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/00003088-198106020-00004","article-title":"Clinical pharmacokinetics of probenecid","volume":"6","author":"Cunningham","year":"1981","journal-title":"Clin Pharm"},{"key":"10.1016\/j.rdc.2012.08.008_bib70","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.2007.083071","article-title":"Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2012.08.008_bib71","unstructured":"Probenecid prescribing information. 2012. Available at: http:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=5ca3dd4c-b8b4-4131-a066-214dabb2576f#nlm34067-9. Accessed June 23, 2012."},{"key":"10.1016\/j.rdc.2012.08.008_bib72","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/00002512-199813030-00006","article-title":"Gout in the elderly. Clinical presentation and treatment","volume":"13","author":"Fam","year":"1998","journal-title":"Drugs Aging"},{"key":"10.1016\/j.rdc.2012.08.008_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12012-011-9145-8","article-title":"The history and future of probenecid","volume":"12","author":"Robbins","year":"2012","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.rdc.2012.08.008_bib74","unstructured":"Allopurinol: drug information: Lexicomp; 2006. Available at: http:\/\/www.uptodate.com\/crlsql\/interact\/frameset.jsp. Accessed July 29, 2012."},{"year":"2011","series-title":"Uloric (febuxostat): prescribing information","key":"10.1016\/j.rdc.2012.08.008_bib75"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X12000671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X12000671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:10:58Z","timestamp":1760181058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X12000671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0889857X12000671"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2012.08.008","relation":{},"ISSN":["0889-857X"],"issn-type":[{"type":"print","value":"0889-857X"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of Urate-Lowering Therapies","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2012.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}